TMDX Maintained by Needham -- Price Target Lowered to $106.00

Needham has maintained a 'Buy' rating on TransMedics Group (TMDX) but lowered its price target from $142.00 to $106.00, reflecting a 25.35% decrease and a more cautious outlook. Despite this, GuruFocus indicates TMDX is 55.4% undervalued, with strong growth potential but challenges in profitability and valuation. Insider activity shows net selling, suggesting some caution among insiders regarding near-term prospects.